Yale researchers developed a controlled-release oral therapy that reversed type 2 diabetes and fatty liver disease in rats, according to a study published on Feb. 26 by Science.
Related Articles
Diabetes mellitus type 1
Diabetes mellitus type 2
Insulin
Diabetes
Glycogen
Animal cognition
Existing therapies for type 2 diabetes, and the closely associated conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), have had limited success at treating the root causes of these diseases. Building on earlier research, the Yale team -- led by Gerald I. Shulman, M.D., the George R. Cowgill Professor of Physiological Chemistry, and professor of medicine and cellular & molecular physiology at Yale School of Medicine -- decided to investigate whether an agent that had originally been used for weight loss more than 70 years ago could be reformulated to safely treat NAFLD/NASH and type 2 diabetes in rodent models of these diseases.
Related Articles
Diabetes mellitus type 1
Diabetes mellitus type 2
Insulin
Diabetes
Glycogen
Animal cognition
Existing therapies for type 2 diabetes, and the closely associated conditions of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), have had limited success at treating the root causes of these diseases. Building on earlier research, the Yale team -- led by Gerald I. Shulman, M.D., the George R. Cowgill Professor of Physiological Chemistry, and professor of medicine and cellular & molecular physiology at Yale School of Medicine -- decided to investigate whether an agent that had originally been used for weight loss more than 70 years ago could be reformulated to safely treat NAFLD/NASH and type 2 diabetes in rodent models of these diseases.
Reversal if Type II and fatty liver disease?
Aucun commentaire:
Enregistrer un commentaire